Published in Cancer Lett on November 20, 2012
MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut (2014) 1.17
Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer (2014) 1.08
Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nat Commun (2014) 1.06
Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med (2014) 1.04
Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol (2015) 1.01
An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. World J Gastroenterol (2014) 0.98
HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut (2014) 0.95
Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer. Oncotarget (2015) 0.90
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer (2016) 0.90
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric Cancer (2013) 0.81
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res (2013) 0.79
Decreased expression of Calpain-9 predicts unfavorable prognosis in patients with gastric cancer. Sci Rep (2016) 0.79
NDRG4 hypermethylation is a potential biomarker for diagnosis and prognosis of gastric cancer in Chinese population. Oncotarget (2016) 0.75
Molecular predictive markers in tumors of the gastrointestinal tract. World J Gastrointest Oncol (2016) 0.75
Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation. Oncol Lett (2015) 0.75
Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer. Medicine (Baltimore) (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet (2009) 58.77
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Next-generation DNA sequencing. Nat Biotechnol (2008) 34.95
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A review of human carcinogens--Part B: biological agents. Lancet Oncol (2009) 13.85
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer (2007) 9.81
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
A decade's perspective on DNA sequencing technology. Nature (2011) 5.61
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
Rules for making human tumor cells. N Engl J Med (2002) 4.84
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Human mutation rate associated with DNA replication timing. Nat Genet (2009) 3.81
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
What would you do if you could sequence everything? Nat Biotechnol (2008) 2.89
How to get genomes at one ten-thousandth the cost. Nat Biotechnol (2008) 2.29
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol (2010) 1.93
An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res (2010) 1.73
Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol (2012) 1.56
Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci (2010) 1.54
Molecular basis of gastric cancer development and progression. Gastric Cancer (2004) 1.49
Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res (2010) 1.41
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res (2010) 1.38
miRNA arm selection and isomiR distribution in gastric cancer. BMC Genomics (2012) 1.35
AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res (2012) 1.31
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med (2011) 1.21
Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol (2000) 1.20
Ultra-deep sequencing reveals the microRNA expression pattern of the human stomach. PLoS One (2010) 1.19
Helicobacter pylori infection generates genetic instability in gastric cells. Biochim Biophys Acta (2010) 1.14
Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol (2009) 1.13
Gastric cancer: basic aspects. Helicobacter (2011) 1.08
Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol (2011) 1.05
Esophagogastric cancer: targeted agents. Cancer Treat Rev (2010) 0.97
AMPKα2 Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis. Genes Cancer (2012) 0.94
Trastuzumab in gastric cancer. Eur J Cancer (2010) 0.92
Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope (2010) 0.91
Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer. Chin J Cancer (2012) 0.82
Assessment of downstream effectors of BCR/ABL protein tyrosine kinase using combined proteomic approaches. Proteomics (2010) 0.79
The homeobox gene Hex regulates hepatocyte differentiation from embryonic stem cell-derived endoderm. Hepatology (2010) 0.94
An electroactive biotin-doped polypyrrole substrate that immobilizes and releases EpCAM-positive cancer cells. Angew Chem Int Ed Engl (2014) 0.87